September 11, 2025Cancer Treatment and Research CommunicationsOpen Access

Systemic therapy breakthroughs in the management of brain metastases: a new era for HER2-positive breast cancer

View Full Paper

Ask AI

Bookmark

Authors

MAMartina Parenza ArenhardtUniversidade Federal do Rio Grande do Sul CVCarolina Martins Vieira ANAngélica Nogueira‐RodriguesUniversidade Federal de Minas Gerais

Discussion

Member takes

Implication

This narrative review demonstrates how antibody-drug conjugates improve outcomes for brain metastases in HER2-positive breast cancer patients, highlighting treatment innovations.

Key Points

Antibody-drug conjugates, like trastuzumab deruxtecan, significantly enhance brain metastasis treatment outcomes.
Recent trials, including the DESTINY-Breast12 trial, revealed a CNS progression-free survival of 17.3 months.
Systemic therapies have changed management of HER2-positive brain metastases, improving overall survival rates.
Current challenges include the role of radiotherapy and the efficacy of therapies against the blood-brain barrier.

Cite This Study

Arenhardt et al. (2025) studied this question.

synapsesocial.com/papers/68d418cd713b0b5dfea64045 https://doi.org/10.1016/j.ctarc.2025.100997

View Full Paper

Ask AI

Bookmark

Implication

This narrative review demonstrates how antibody-drug conjugates improve outcomes for brain metastases in HER2-positive breast cancer patients, highlighting treatment innovations.

Systemic therapy breakthroughs in the management of brain metastases: a new era for HER2-positive breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Systemic therapy breakthroughs in the management of brain metastases: a new era for HER2-positive breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider